Barclays’s Innate Pharma IPHA Stock Holding History

Barclays’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$2	–	5238
2025 Q4	$2	Sell	1 -306	-100%	-$591	﹤0.01%	5178
2025 Q3	$593	Hold	307	–	–	﹤0.01%	5197
2025 Q2	$557	Hold	307	–	–	﹤0.01%	5075
2025 Q1	$546	Hold	307	–	–	﹤0.01%	5078
2024 Q4	$565	Hold	307	–	–	﹤0.01%	5158
2024 Q3	$703	Sell	307 -105	-25%	-$232	﹤0.01%	5134
2024 Q2	$799	Hold	412	–	–	﹤0.01%	4695
2024 Q1	$1.19K	Hold	412	–	–	﹤0.01%	4942
2023 Q4	$1.15K	Hold	412	–	–	﹤0.01%	5106
2023 Q3	$1.04K	Hold	412	–	–	﹤0.01%	4493
2023 Q2	$1.27K	Hold	412	–	–	﹤0.01%	4351
2023 Q1	$1.17K	Hold	412	–	–	﹤0.01%	4918
2022 Q4	$1.54K	Buy	412 +289	+235%	+$659	﹤0.01%	5100
2022 Q3	$0	Sell	123 -2,056	-94%	-$5.55K	﹤0.01%	4956
2022 Q2	$6K	Sell	2,179 -1,232	-36%	-$3.58K	﹤0.01%	4747
2022 Q1	$11K	Buy	+3,411	New	+$12.6K	﹤0.01%	4585

Other funds holding IPHA

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Barclays's IPHA Position: Q1 2026 in Review

Barclays sold out of Innate Pharma (IPHA) in Q1 2026, closing a stake of 1 share — an estimated $2 sold.

Barclays first reported a position in IPHA in Q1 2022 and held it in 16 quarters. The position peaked at $11K in Q1 2022. 9 funds tracked by Wall St. Rank hold IPHA as of Q1 2026.

Barclays reported no remaining Innate Pharma position as of Q1 2026 after selling out during the quarter.
Barclays sold 1 Innate Pharma share in Q1 2026, an estimated $2.
Barclays first reported a position in Innate Pharma in Q1 2022 and held it in 16 quarters.
Barclays's Innate Pharma position peaked at $11K in Q1 2022.
9 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.